What does CDT stand for?

Clostridium Difficile Toxin (bacteria)

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Chalk Dust Torture (Phish song) Change Detection Tool Chargeable Down Time Chemical Deposition Technique China Digital Times Class Descriptor Table Client Development Tool (Intel) Cliff Drysdale Tennis (various locations) Clinical Dental Technician (various locations) Clock Doesn't Tick		Collaborative Development Team Command Descriptor Table (NASA) Commercial Desktop (computer) Commissioner's Disability Table Common Data Transistor Common Data Translator Community Development Trust (various organizations) Community Drugs Team (UK) Complete Decongestive Therapy (lymphedema management) Completely Decomposed Tuff

Samples in periodicals archive:

Where I am going is to the New England Journal of Medicine, January 21, 2010, where a 12-week double-blind trial was published demonstrating that treatment with monoclonal antibodies against Clostridium difficile toxins significantly reduced the recurrence rate of C.

Caviar among the ruins

The nine bacterial pathogens targeted in the GI panel include Clostridium difficile; Clostridium difficile toxin B gene; Campylobacter jejuni; Escherichia coli strain 0157; Listeria monocytogenes; Salmonella enterica; Staphylococcus aureus; Vibrio cholerae; and Vibrio parahaemolyticus.

DIATHERIX Laboratories Introduces Gastrointestinal Test Panel; Test ...

Evaluation of two rapid assays for detection of Clostridium difficile toxin A in stool specimens.

Real-time PCR testing for CDI improves outcomes and reduces costs

Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B.

Clostridium difficile: association with thrombocytosis and ...

Lack of value of repeat stool testing for Clostridium difficile toxin.

Clostridium Difficile-Associated Disease

NASDAQ: MEDX) and Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that they have signed an exclusive worldwide license agreement for CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and MBL-CDA1/MBL-CDB1), an investigational fully human monoclonal antibody combination developed to target and neutralize Clostridium difficile toxins A and B, for the treatment of C.

Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic ...

Revised nomenclature of Clostridium difficile toxins and associated genes.

Possible seasonality of clostridium difficile in retail meat, Canada

Saccharomyces boulardii Protease Inhibits the Effects of Clostridium difficile Toxins A and B in Human Colonic Mucosa.

Abstract & Commentary: Weigh the cons against probiotics